Recent advances of TNF-α antagonists in rheumatoid arthritis and chronic heart failure

Bibliography

• TRACEY KJ, CERAMI A: Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu. Rev. Med. (1994) 45:491-503.
   PubMed Web of Science ®Google Scholar
• TRACEY KJ, CERAMI A: Metabolic response to cachectin/TNF. Annals of the New York Academy of Sciences. Volume 587. Boland B, Cullinan J, Kimball C (Eds), New York Academy of Sciences, New York, USA (1990):325-330.
   Google Scholar
• MURRAY J, BARBARA J, DUNKLEY S et al.: Regulation of neutrophil apoptosis by tumor necrosis factor-alpha: requirements for TNF-R55 and TNF-R75 for induction of apoptosis in vitro. Blood (1997) 90:2772-2783.
   PubMed Web of Science ®Google Scholar
• CARSWELL E, OLD L, KASSEL R et al.: An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA (1975) 72:3666-3670.
   PubMed Web of Science ®Google Scholar
• CHOY ES, PANAYI GS: Cytokine pathway and joint inflammation in rheumatoid arthritis. N. Engl. J. Med. (2001) 344:907-916.
   PubMed Web of Science ®Google Scholar
• DINARELLO CA: Proinflammatory cytokines. Chest (2000) 118:503-508.
   PubMed Web of Science ®Google Scholar
• OPAL SM, DEPALO VA: Anti-inflammatory cytokines. Chest (2000) 117:1162-1172.
   PubMed Web of Science ®Google Scholar
• FELDMANN M, MAINI RN: Lasker Clinical Medical Research Award: TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat. Med. (2003) 9:1245-1250.
   PubMed Web of Science ®Google Scholar
• GULLI S, ARRIGO C, BOCCHINO L et al.: Remission of Behcet’s disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet. Disord. (2003) 4:2471-2474.
   Google Scholar
• SFIKAKIS PP, THEODOSSIADIS PG, KATSIARI CG, KAKLAMANIS P, MARKOMICHELAKIS NN: Effect of infliximab on sight-threatening panuveitis in Bechet’s disease. Lancet (2001) 35:295-296.
   Google Scholar
• EFTHIMIOU P, SCHWARTZMAN S, KAGEN LJ et al.: Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann. Rheum. Dis. (2006) 65:1233-1236.
   Google Scholar
• MORELAND LW, WEINBLATT ME, KEYSTONE EC et al.: Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J. Rheumatol. (2006) 33:831-833.
   PubMed Web of Science ®Google Scholar
• CHEN YF, JOBANPUTRA P, BARTON P et al.: A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol. Assess. (2006) 10:1-248.
   Web of Science ®Google Scholar
• NICOLA PJ, MARADIT-KREMERS H, ROGER VL et al.: The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum. (2005) 52:412-420.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. (2004) 116:305-311.
   PubMed Web of Science ®Google Scholar
• BENNETT S, CASEY DE, GANIATS TG et al.: ACC/AHA clinical performance measures for adults with chronic heart failure. J. Am. Coll. Cardiol. (2005) 46:1145-1178.
   Google Scholar
• REMME WJ, SWEDBERG K: Comprehensive guidelines for the diagnosis and treatment of chronic heart failure: task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur. Soc. Cardiol. (2002) 4:11-22.
   Web of Science ®Google Scholar
• LEVINE B, KALMAN J, MAYER L et al.: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. (1990) 223:236-241.
   Google Scholar
• YOKOYAMA T, VACA L, ROSSEN RD et al.: Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J. Clin. Invest. (1993) 92:2303-2312.
   PubMed Web of Science ®Google Scholar
• KADOKAMI T, MCTIERNAN CF, KUBOTA T et al.: Effects of soluble TNF receptor treatment on lipopolysaccharide-induced myocardial cytokine expression. Am. J. Physiol. Heart Circ. Physiol. (2001) 280:2281-2291.
   Web of Science ®Google Scholar
• BOZKURT B, KRIBBS SB, CLUBB FJ JR et al.: Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation (1998) 97(14):1382-1391.
   PubMed Web of Science ®Google Scholar
• PAGANI FD, BAKER LS, HIS C, KNOX M, FINK MP, VISNER MS: Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. J. Clin. Invest. (1992) 90(2):389-398.
   PubMed Web of Science ®Google Scholar
• MURRAY DR, FREEMAN FL: Tumor necrosis factor-alpha induces a bisphasic effect on myocardial contractility in conscious dogs. Circ. Res. (1996) 78(1):154-160.
   PubMed Web of Science ®Google Scholar
• KUBOTA T, MCTIERNAN CF, FRYE CS et al.: Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ. Res. (1997) 81(4):627-635.
   PubMed Web of Science ®Google Scholar
• DIBBS ZI, DIWAN A, NEMOTO S et al.: Targeted overexpression of transmembrane tumor necrosis factor provokes a concentric cardiac hypertrophic phenotype. Circulation (2003) 108(8):1001-1008.
   Google Scholar
• KURRELMEYER KM, MICHAEL LH, BAUMGARTEN G et al.: Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model for acute myocardial infarction. Proc. Natl. Acad. Sci. USA (2000) 97(10):5456-5461.
   PubMed Web of Science ®Google Scholar
• MISRA A, HAUDEK SB, KNUEFERMANN P et al.: Nuclear factor-kappaB protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. Circulation (2003) 108(25):3075-3078.
   PubMed Web of Science ®Google Scholar
• TORRE-AMIONE G, KAPADIA S, LEE J, BIES RD, LEBOVITZ R, MANN DL: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation (1995) 92(6):1487-1493.
   PubMed Web of Science ®Google Scholar
• MANN DL: Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ. Res. (2002) 91(11):988-998.
   PubMed Web of Science ®Google Scholar
• ORAL H, DORN GW, MANN DL: Sphingosine mediates the immediate negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian cardiac myocyte. J. Biol. Chem. (1997) 272(8):4836-4842.
   PubMed Web of Science ®Google Scholar
• KROWN KA, YASUI K, BROOKER MJ et al.: TNF alpha receptor expression in rat cardiac myocytes: TNF alpha inhibition of L-type Ca2+ current and Ca2+ transients. FEBS Lett. (1995) 376(1-2):24-30.
   PubMed Web of Science ®Google Scholar
• GULICK T, CHUNG MK, PIEPER SJ, LANGE LG, SCHREINER GF: Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness. Proc. Natl. Acad. Sci. USA (1989) 86(17):6753-6757.
   PubMed Web of Science ®Google Scholar
• KROWN KA, PAGE MT, NGUYEN C et al.: Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signaling cascade in cardiac cell death. J. Clin. Invest. (1996) 98(12):2854-2865.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA T, NAKANO M, BEDNARCZYK JL, MCINTYRE BW, ENTMAN M, MANN DL: Tumor necrosis factor-alpha provokes a hypertrophic growth response in adult cardiac myocytes. Circulation (1997) 95(5):1247-1252.
   PubMed Web of Science ®Google Scholar
• LI YY, FENG YQ, KADOKAMI T et al.: Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc. Natl. Acad. Sci. USA (2000) 97(23):12746-12751.
   PubMed Web of Science ®Google Scholar
• WADA H, SAITO K, KANDA T et al.: Tumor necrosis factor-α plays a protective role in acute viral myocarditis in mice. Circulation (2001) 103:743-749.
   PubMed Web of Science ®Google Scholar
• DESWAL A, BOZKURT B, SETA Y et al.: Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation (1999) 99:3224-3226.
   PubMed Web of Science ®Google Scholar
• BOZKURT B, TORRE-AMIONE G, WARREN MS et al.: Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation (2001) 103:1044-1047.
   PubMed Web of Science ®Google Scholar
• MANN DL, MCMURRAY JJ, PACKER M et al.: Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 109:1594-1602.
   PubMed Web of Science ®Google Scholar
• CHUNG ES, PACKER M, LO KH et al.: Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure, results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation (2003) 107:3133-3140.
   PubMed Web of Science ®Google Scholar
• KWON HJ, COTE TR, CUFFE MS et al.: Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann. Intern. Med. (2003) 138:807-811.
   PubMed Web of Science ®Google Scholar
• DE’ CLARI F, SALANI I, SAFTWAN E et al.: Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-{alpha} have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? Circulation (2002) 105:e183.
   PubMed Web of Science ®Google Scholar